186 related articles for article (PubMed ID: 34805170)
1. Clinical and Immunological Effects of p53-Targeting Vaccines.
Zhou S; Fan C; Zeng Z; Young KH; Li Y
Front Cell Dev Biol; 2021; 9():762796. PubMed ID: 34805170
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen vaccines for prostate cancer.
Hörig H; Lee CS; Kaufman HL
Expert Opin Biol Ther; 2002 Apr; 2(4):395-408. PubMed ID: 11955277
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.
Vermeij R; Leffers N; van der Burg SH; Melief CJ; Daemen T; Nijman HW
J Biomed Biotechnol; 2011; 2011():702146. PubMed ID: 21541192
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
5. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA; Soyano AE; Dholaria B; Knutson KL; Lou Y
J Hematol Oncol; 2018 Jan; 11(1):8. PubMed ID: 29329556
[TBL] [Abstract][Full Text] [Related]
7. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
8. Vaccines for multiple sclerosis: progress to date.
Correale J; Farez M; Gilmore W
CNS Drugs; 2008; 22(3):175-98. PubMed ID: 18278975
[TBL] [Abstract][Full Text] [Related]
9. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
10. Development of vaccines against self-antigens: the p53 paradigm.
Chada S; Mhashilkar A; Roth JA; Gabrilovich D
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
[TBL] [Abstract][Full Text] [Related]
11. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Mahdavi A; Monk BJ
Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells.
Sadeghi Najafabadi SA; Bolhassani A; Aghasadeghi MR
Immunotherapy; 2022 Jun; 14(8):639-654. PubMed ID: 35481358
[TBL] [Abstract][Full Text] [Related]
13. Advances in prostate cancer immunotherapies.
Basler M; Groettrup M
Drugs Aging; 2007; 24(3):197-221. PubMed ID: 17362049
[TBL] [Abstract][Full Text] [Related]
14. Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.
Huang J; Harris E; Lorch J
Oral Oncol; 2022 Dec; 135():106083. PubMed ID: 36332445
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of cellular vaccine in glioma: current advances and future prospects.
Yan Y; Zeng S; Gong Z; Xu Z
J Exp Clin Cancer Res; 2020 Nov; 39(1):257. PubMed ID: 33228738
[TBL] [Abstract][Full Text] [Related]
16. Progress in Vaccine Therapies for Breast Cancer.
Li X; Bu X
Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific immunotherapy of cervical and ovarian cancer.
Hung CF; Wu TC; Monie A; Roden R
Immunol Rev; 2008 Apr; 222():43-69. PubMed ID: 18363994
[TBL] [Abstract][Full Text] [Related]
18. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
[TBL] [Abstract][Full Text] [Related]
19. Nanobiomaterial-based vaccination immunotherapy of cancer.
Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
[TBL] [Abstract][Full Text] [Related]
20. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
